Gabapentin
Product Images NDC 64205-222

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 64205-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Readymeds, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

7d5ebe51-figure-01 (7d5ebe51 Figure 01)

Chemical structure diagram of Gabapentin showing its molecular arrangement with annotations for functional groups including amine (CH2NH2) and carboxyl (CH2CO2H) groups attached to a cyclohexane ring.*

FDA Label Image

7d5ebe51-figure-02 (7d5ebe51 Figure 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo to Gabapentin at 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a notable decrease in pain scores compared to placebo throughout the study.*

FDA Label Image

7d5ebe51-figure-03 (7d5ebe51 Figure 03)

A line graph showing the mean pain score over 7 weeks comparing placebo and gabapentin at 1800 mg/day and 2400 mg/day. The x-axis represents weeks during a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10. The graph indicates changes in pain score for each group over time.*

FDA Label Image

7d5ebe51-figure-04 (7d5ebe51 Figure 04)

A bar chart showing the percentage of responders at endpoint for two studies comparing placebo (PBO) and Gabapentin (GBP) at different doses: 3600 mg in Study 1 and 1800 mg and 2400 mg in Study 2. The chart indicates higher responder rates for Gabapentin compared to placebo with statistical significance markers.*

FDA Label Image

7d5ebe51-figure-05 (7d5ebe51 Figure 05)

A scatter plot graph showing the percentage difference on the y-axis and daily dose in milligrams on the x-axis with data points from three studies labeled as STUDY a, STUDY b, and STUDY c. Each study's data points are marked with different colored squares (black, gray, and white) plotted across doses 600 mg to 1800 mg with annotations a, b, and c near some points.*

FDA Label Image

Photo (Photo)

The label on a ReadyMeds packaging for Gabapentin 300 mg tablets. The package contains 30 tablets. The label displays the NDC number 64205-222-30, expiration date of 02/2018, and lot number I1403688.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.